Orexin Agonist Oveporexton Approved for Narcolepsy Type 1

Takeda's ORZEYFUL (oveporexton) has been approved in Japan, China, and the United States as the first oral orexin receptor 2 agonist for narcolepsy type 1. The drug is designed to address the core orexin deficiency that causes the chronic neurological condition, moving beyond traditional symptom management.

A Shift in Treatment Paradigm

Historically, narcolepsy type 1 treatment has focused on managing individual symptoms like excessive daytime sleepiness and cataplexy. Oveporexton represents a fundamental shift by targeting the disease mechanism itself. It selectively stimulates the orexin receptor 2 to restore signaling pathways. Experts herald this as a new direction for patient care.

“I look forward to seeing a broader range of treatment options become available, helping physicians tailor treatment to the needs of each individual patient,” says Yuichi Inoue, MD, a professor at Tokyo Medical University, in a statement provided by Takeda.

Global Regulatory Approvals

The drug secured approvals in three major markets within a short timeframe. The Japanese Ministry of Health, Labour and Welfare approved it for adults in August. China's National Medical Products Administration approved it for adolescents aged 16 and older and adults in July. The US Food and Drug Administration granted approval for adults, also in August.

In China, narcolepsy is estimated to affect about 700,000 people. Narcolepsy type 1 accounts for roughly 75% to 80% of those cases, according to Takeda.

Clinical Trial Results

The approvals are grounded in data from the Phase 3 FirstLight and RadiantLight studies. These 12-week trials compared oveporexton to a placebo, evaluating its efficacy, safety, and tolerability. The results showed statistically significant improvements on key endpoints, including reductions in excessive daytime sleepiness and cataplexy attacks.

The trials also measured positive outcomes on several secondary endpoints. These included assessments of daily functioning and quality of life.

Expert Perspectives on Patient Impact

Sleep specialists emphasize the potential impact of this mechanism-driven approach. Han Fang, director of the sleep medicine center at Peking University People's Hospital, stated the approval signals a transition from partial symptom management to a treatment that may help address the many symptoms evaluated in clinical studies. He suggested it could support improvements in daily functioning and quality of life.

In the United States, Emmanuel Mignot, MD, PhD, principal investigator in the Phase 3 program, noted the change this drug brings to clinical conversations. As the first and only approved orexin therapy to treat the broad spectrum of the disease, ORZEYFUL can enable a different kind of conversation in the doctor’s office about treatment options, Mignot said in a release. The most frequently reported adverse reactions during trials were insomnia, urinary urgency, urinary frequency, and excessive saliva production.